Myfenax (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Myfenax, is an antimetabolite presented as a tablet for oral use. It is employed to prevent rejection of transplanted organs in patients who have received kidney, liver, heart or other solid‑organ transplants.

GNH USA supplies Myfenax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution. Customers benefit from reliable lead times, secure packaging and responsive technical support throughout the supply chain.

Myfenax, containing mycophenolate mofetil, is used in the immunosuppressive management of solid‑organ transplantation, often as part of a combination regimen with calcineurin inhibitors and steroids. - Kidney transplantation: helps prevent acute and chronic graft rejection. - Liver transplantation: reduces the incidence of rejection episodes and supports graft survival. - Heart transplantation: provides maintenance immunosuppression to lower rejection risk. - Pancreas transplantation: contributes to rejection prophylaxis and improves graft function. - Lung transplantation: aids in preventing graft rejection and supports long‑term graft viability.

Myfenax may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools. - Headache: transient cranial discomfort. - Tremor: mild shaking of hands or limbs. - Vomiting: occasional episodes of emesis. - Abdominal pain: cramp‑like discomfort. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Infections: opportunistic or severe bacterial, viral or fungal infections. - Bone marrow suppression: leukopenia, anemia or thrombocytopenia. - Malignancy: increased risk of lymphoproliferative disorders and skin cancers. - Liver enzyme elevation: increased transaminases indicating hepatic stress. - Pregnancy loss: fetal malformations and embryotoxicity (category X).

When prescribing Myfenax, clinicians should observe several precautionary measures to minimize risk. - Monitor blood counts: perform regular complete blood count tests to detect leukopenia or anemia. - Assess renal function: adjust dosing in patients with impaired kidney function. - Avoid pregnancy: discontinue before conception and use effective contraception. - Vaccination caution: avoid live vaccines during treatment. - Drug interactions: review concomitant medications that may increase mycophenolate exposure. - Store at room temperature: keep tablets below 25 °C in the original container, protected from moisture.

Myfenax can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Live vaccines: may cause severe infection due to immunosuppression. - Azathioprine: additive bone marrow suppression increases risk of cytopenias.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may reduce mycophenolate absorption; separate dosing by at least 2 hours. - Cyclosporine or tacrolimus: may increase mycophenolate exposure; monitor drug levels and adjust dose. - Warfarin: may enhance anticoagulant effect; check INR more frequently.